Expectations trend
FY2028 · fiscal year ending 2028-04-30 · fmp
FY2028 EPS: comparable history unavailable.
Champions Oncology Inc (CSBR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.76-1.45%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
No analysts cover EPS estimates for this fiscal period.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CSBR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve positive adjusted EBITDA for fiscal year | Champions Oncology aims to reach positive adjusted EBITDA this fiscal year. | Intact | adjusted EBITDA remains negative through FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-04-30 · fmp
FY2028 EPS: comparable history unavailable.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 21, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth business, not yet a proven durable compounder, and current results are weak. The multi-year view depends on revenue growth and investment in proprietary data and radiopharmaceutical capabilities translating into stronger operating performance.
CSBR is described as cheap versus peers, but confidence in the valuation model is low. The expectations gap is negative, while priced-in fragility is low and tagged as justified, so the evidence does not point to fragile expectations already embedded in the valuation.
Near term, revenue has grown and fiscal 2026 revenue reached a record, while adjusted EBITDA remained positive but fell substantially from the prior year; the company is still classified as loss-making. The recent earnings miss and a 53% estimated miss probability make the next report a key risk, despite management continuing to invest in data and radiopharmaceutical capabilities.
The multi-year thesis hinges on revenue growth continuing and those investments supporting improved results without eroding profitability. Near term, a guidance cut or further weakening in jobs data could weigh on cyclical healthcare businesses, while strong results and guidance from sector bellwethers could support sector momentum.
Over the next 1 to 3 years, CSBR offers a cheap-versus-peers valuation alongside real growth efforts, but weak performance, loss-making earnings quality, and high risk leave the thesis unproven. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The new CEO hired in 2025 brings stable leadership. |
| Intact |
| CEO departs within 12 months |
CEO stable vs no departure target News shows revenue growth and EBITDA improvement; no CEO departure reported in recent events. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize revenue near $65 million | Revenue is expected near $65 million next year. | Intact | revenue falls below $60 million next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain valuation discount to peers | A supporting condition in Champions Oncology Inc's published investment case. The stated target is EV/EBITDA <= 15 and FCF yield >= 5%. | Intact | EV/EBITDA rises above 20 or FCF yield falls below 3% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.07B → $0.07B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-25 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-26 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-27 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-28 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-29 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-30 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-07-31 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-01 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-02 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-03 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-04 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-05 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-06 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-07 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-08 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-09 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-10 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-11 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-12 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-13 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-14 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-15 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-16 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-17 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-18 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-19 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-20 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-21 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-22 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-23 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-24 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-25 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-26 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-27 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-28 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-29 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-30 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-08-31 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-01 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-02 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-03 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-04 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-05 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-06 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-07 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-08 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-09 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-10 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-11 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-12 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-13 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-14 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-15 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-16 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-17 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-18 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-19 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-20 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-21 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-22 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-23 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-24 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-25 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-26 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-27 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-28 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-29 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-09-30 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-01 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-02 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-03 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-04 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-05 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-06 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-07 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-08 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-09 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-10 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-11 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-12 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-13 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-14 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-15 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-16 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-17 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-18 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-19 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-20 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-21 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-22 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-23 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-24 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-25 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-26 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-27 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-28 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-29 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-30 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-10-31 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-11-01 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-11-02 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-11-03 | Unavailable | $70,811,000 | 0 / 1 |
| 2026-11-04 | Unavailable | $70,811,000 | 0 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.